

## RESEARCH ARTICLE

# Color coded perfusion imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following trans-arterial chemoembolization (TACE) of hepatocellular carcinoma



Janine Rennert<sup>ID</sup>\*<sup>●</sup>, Isabel Wiesinger<sup>●</sup>, Andreas Schicho, Lukas Philip Beyer<sup>ID</sup>, Philipp Wiggemann, Christian Stroszczynski, Ernst Michael Jung

University Hospital Regensburg, Department of Radiology, Regensburg, Germany

● These authors contributed equally to this work.

\* [jarennett@yahoo.de](mailto:jarennett@yahoo.de)

## Abstract

### OPEN ACCESS

**Citation:** Rennert J, Wiesinger I, Schicho A, Beyer LP, Wiggemann P, Stroszczynski C, et al. (2019) Color coded perfusion imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following trans-arterial chemoembolization (TACE) of hepatocellular carcinoma. PLoS ONE 14(6): e0217599. <https://doi.org/10.1371/journal.pone.0217599>

**Editor:** Gianfranco D. Alpini, Texas A&M University, UNITED STATES

**Received:** March 24, 2019

**Accepted:** May 14, 2019

**Published:** June 10, 2019

**Copyright:** © 2019 Rennert et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data is within the paper and its Supporting Information files.

**Funding:** The authors received no specific funding for this work.

**Competing interests:** The authors have declared that no competing interests exist.

## Aim

Evaluation of an external color coded perfusion quantification software with CEUS for the post-interventional success control following TACE in patients with HCC.

## Material and methods

31 patients (5 females, 26 males, age range 34–82 years, mean 66.8 years) with 59 HCC lesions underwent superselective TACE using DSM Beads between 01/2015 and 06/2018. All patients underwent CEUS by an experienced examiner using a convex multifrequency probe (1–6 MHz) within 24 hours following TACE to detect residual tumor tissue. Retrospective evaluation using a perfusion quantification software regarding pE, TTP, mTT, Ri and WiAUC in the center of the lesion, the margin and surrounding liver.

## Results

In all lesions, a post-interventional visual reduction of the tumor microvascularization was observed. Significant differences between center of the lesion vs. margin and surrounding liver were found regarding peak enhancement ( $867.8 \pm 2416$  center vs  $2028 \pm 3954$  margin  $p<0.005$ ) and center  $867.8 \pm 2416$  vs  $2824 \pm 4290$  surrounding liver,  $p<0.0001$ ). However, no significant differences were found concerning Ri, WiAuC, mTT and TTP.

## Conclusion

CEUS with color-coded perfusion imaging is a valuable supporting tool for post-interventional success control following TACE of liver lesions. Peak enhancement seems to be the most valuable parameter.

## Introduction

Liver lesions are the sixth most common cancer (approximately 750,000 new cases per year) and currently represent the third most common cause of cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) shows an increasing incidence and generates over 90% of all primary hepatic cancers, thus representing a major healthcare problem [1].

HCC has a strong male predominance with an estimated male to female ratio of 2.4 [1]. Approximately 90% of HCCs are associated with known underlying risk factors. The most frequent factors include chronic viral hepatitis (types B and C), alcohol intake and aflatoxin exposure [2].

Hepatic cirrhosis is an important risk factor for HCC, commonly caused by chronic viral hepatitis, alcohol, inherited metabolic diseases such as hemochromatosis or alpha-1-antitrypsin deficiency, and non-alcoholic fatty liver disease. All etiologic forms of cirrhosis may be complicated by tumor formation, but the risk is higher in patients with hepatitis with 2–8% per year [3]. Various published guidelines agree on a typical vascular pattern of HCC lesions, being characterized by early arterial enhancement followed by contrast media wash-out beginning in the venous phase [4–6]. Small tumor lesions < 1 cm often display no venous wash out at all. The imaging modalities recommended for diagnosis of HCC include contrast enhanced magnetic resonance imaging (MRI), multi-phase contrast enhanced computed tomography (CT) and contrast enhanced ultrasound (CEUS). Current studies have shown a sensitivity for detection of HCC of up to 91.1% for CEUS [7–9] up to 87.5% for CT [10] and up to 95.9% for Gd-EOB-DTPA-Enhanced Liver MRI (Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid) [11].

Depending on the local tumor extent, extrahepatic spread and the established degree of liver damage, various therapeutic options are available for each stage. For early stage HCC surgical resection [12], ablation [13] and transplantation [14] are recommended. Furthermore trans-arterial chemoembolization (TACE) [15] is suggested for intermediate-stage HCC, sorafenib for advanced-stage HCC [16]. Finally, for terminal-stage HCC best supportive care is advised [5].

TACE is commonly used in two settings, either in HCC unsuitable for resection or ablation or liver transplantation as a bridge therapy [17]. The aim of TACE is to pad the tumor with a chemotherapeutic drug (eg, doxorubicin, epirubicin, cisplatin, or mitomycin C) using a carrier agent. Formerly, Lipiodol was used as the carrier agent, but this has been largely replaced by drug-eluting beads, which are available in different sizes [18].

Aim of this study was the evaluation of an external color coded perfusion quantification software with CEUS for the post-interventional success control following TACE in patients with HCC.

## Material and methods

### Study design

From January 2015 until June 2018, 31 patients (26 males, 5 females, age 34–82 years, mean 62.8 years) with 59 HCCs, identified by characteristic imaging features or histopathology were included in this retrospective study. Each patient underwent pre-interventional contrast-enhanced computed tomography (CT) and liver specific contrast enhanced magnetic resonance imaging (MRI) for detection and characterization of the liver lesions within 72 hours prior to the intervention. The study was approved by the University medical Center Regensburg ethics Committee (reference number 15-104-0115).

The therapeutic interventional procedure for each patient was a superselective trans-arterial chemoembolization (TACE) using degradable starch microspheres (DSM; EmboCept S, PharmaCept, Germany) loaded with 50 mg Epirubicin (Famorubicin, Pfizer, USA). The indication for a TACE was formed by an interdisciplinary tumor conference.

Each patient was examined using B-mode, Color Coded Doppler Sonography (CCDS), Power Doppler and Contrast Enhanced Ultrasound (CEUS). Before the imaging procedures were conducted, written informed consent was obtained from each patient for MRI, CT and CEUS. Exclusion criteria of this study were contraindications for use of a contrast agent for CT, MRI or CEUS, impaired renal function (creatinine  $>1.5$  mg/dl, creatinine clearance  $< 30$  ml/min), pre-existing strong allergic reactions and decompensated cardiac failure.

## Imaging studies

**Basic ultrasound examination.** Within 24 hours following TACE, ultrasound was performed by an experienced radiologist with national DEGUM stage III using a multifrequency convex transducer (1–6 MHz, LOGIQ E9, GE Healthcare).

First, the whole liver was examined using B-mode sonography in sweep technique. Color Coded Doppler Sonography (CCDS) and Power Doppler (PD) ultrasound were used to evaluate macro vascularization. Flow parameters were adjusted to the lowest possible pulse repetition frequency (PRF  $< 1000$  Hz) and the best possible color imaging without blooming artifacts.

**CEUS.** Contrast enhanced ultrasound (CEUS) was performed after bolus injections of 1–2.4 ml of sulphur hexafluoride microbubbles (SonoVue, BRACCO, Italy) with a low mechanical index (MI  $< 0.16$ ) applying CEUS with amplitude modulation and pulse inversion harmonic imaging (PIHI) technique. The contrast harmonic imaging technique (CHI) uses a contrast-specific detection mode for real-time evaluation of the contrast-agent enhancement. The complete data of the contrast-agent examination was recorded up to 5 min. The liver microcirculation was evaluated continuously from an early arterial phase (beginning 15 sec. after contrast application) until a late parenchymal phase ( $> 5$  min.). The transducer was held steadily on the post-embolisation defect of 1 minute to avoid repeated injection of contrast media, afterwards the whole liver was examined in sweep technique to look for wash-out. The first minute was documented a video clip. Afterwards single images were stored until the late phase. All images were digitally stored in PACS.

Irregular enhancement in the periphery of the embolized area during early arterial phase, ideally combined with a wash-out starting during portal venous phase was seen as a characteristic criterion for residual HCC tissue. A uniform peripheral rim enhancement without wash-out was considered as physiological postembolization reaction. Wedge-shaped, homogenous arterial enhancement peripheral to the embolized area with progressively enhancing portal-venous branching but without washout was defined as arterio-portal-venous shunt.

CEUS was performed within 24 hours prior and following the procedure.

**CT/ MRI.** Each patient received a pre- and post-interventional contrast-enhanced dual source CT (ceCT) of the liver in arterial phase (25–35 sec), in portal-venous phase (70–90 sec) and late phase ( $>120$  sec) with bolus injection of iodic contrast-agent (100–130 ml Accupaque, GE) (SOMATOM Definition Flash Siemens Healthcare, Erlangen Germany; collimation 5 mm with coronary and axial reconstructions). Before the treatment every patient received a ceCT of the whole abdomen/ pelvis in portal-venous phase to exclude extrahepatic tumor manifestation. Within 24 hours after the treatment only the liver was scanned in arterial and portal-venous phase to exclude post-interventional complications.

An additional pre-interventional contrast-enhanced MRI (ceMRI) was performed (Skyra 3T, Siemens Healthcare, Erlangen, Germany), using T1/ T2 sequences, diffusion imaging with

ADC as well as contrast-enhanced sequences after bolus injection of 15–35 ml liver specific contrast agent (Gd-EOB-DTPA), (Primovist, Bayer, Schering Pharma AG, Germany) using 3D vibe sequences from arterial phase (20–25 sec) up to late phase.

For follow-up, patients received CEUS, MRI and CT scans according to the protocols mentioned above for up to 6 months.

**Perfusion analysis.** The digitally stored ultrasound loops were evaluated using a color coded perfusion quantification software (VueBox, Bracco, Italy) on a separate computer. DICOM loops were uploaded and opened in the VueBox platform (BRACCO, Italy) for blinded and independent reading. VueBox is a color-coded off-line general-purpose perfusion software for dynamic CEUS examinations, that uses automatic in-plane motion correction [19]. Four parameters were calculated for each Region of interest (ROI) which included time to peak (TTP), mean transit time (mTT), peak enhancement (pE), Wash-in Area Under the Curve (WiAUC) and Rise (Ri). Flow parameters such as regional blood volume and regional blood flow were calculated by the software and exported in a calculation protocol.

Regions of Interest (ROI) were manually placed in the center of the lesion, at the margins and the surrounding liver tissue > 2cm distance. The VueBox screen is divided into four quadrants: in the upper left quadrant the original image with the ROIs is displayed, in the upper right quadrant the corresponding parametric image is displayed, in the lower left quadrant the corresponding time/intensity curves are shown in the color corresponding to the ROI in the image above and in the lower right quadrant the respective numerical values of the selected curve parameter is shown [20, 21] (image 2).

## Imaging analysis

CEUS examinations and the perfusion analysis were read by two experienced radiologists in consensus. For each modality, each observer recorded the diagnostic findings. Furthermore, the image quality was documented on a four points scale: 1—excellent, 2—minor diagnostic limitations, 3 –major diagnostic limitations, 4—non-diagnostic.

Imaging modalities were evaluated using the data analysis hard-/software of the ultrasound system (LOGIQ E9, GE).

## Statistical analysis

For data analysis, IBM-SPSS software (version 19.0, SPSS Inc., Chicago, USA) was used.

For calculation of the differences between the center of the lesion and the margins, the margins and the surrounding liver as well as the center of the lesion and the surrounding liver for each parameter repeated measures ANOVA with Bonferroni post test was performed using GraphPad Prism version 5.00 for Mac OS X, GraphPad Software, San Diego California USA with alpha = 0.05 indicating statistically significant differences between groups.

## Results

### Lesions characteristics and tumor size

Each of the 59 tumor lesions showed an enhancement pattern consistent with hepatocellular carcinoma (HCC) including arterial irregular hyperenhancement and portal venous washout on CEUS. Also, the pre-interventional imaging techniques showed characteristics compatible with HCC. All 31 patients underwent pre-interventional MRI using a liver specific contrast agent (Primovist, Bayer HealthCare AG, Germany; 0.1 ml/kg body weight) and a pre-interventional CT. Also, post-interventional CT scans were performed within 24 hours after the

procedure to identify complications. During the 6 months follow-up, all patients with recurrent disease were correctly identified using CEUS.

The pre-interventional tumor sizes of the 59 lesions ranged from 9 mm up to 55 mm with a mean size of 36 mm. The post-interventional defects sized from 11 mm to 55 mm with a mean size of 31 mm. In all lesions, a post-interventional reduction of the tumor microvascularization was observed.

### Perfusion analysis and CEUS

In all 31 patients (100%) CEUS was viable. The image quality in all examinations was excellent or had only minor diagnostic limitations ( $1-2 \text{ SD} \pm 0.372$ ).

The data acquired for pE, WiAuC, mTT, TTP and Ri is shown in [Table 1](#). No significant differences between center of the lesion vs. margin, margins vs. surrounding liver and center of the lesion vs. surrounding liver were found regarding WiAuC, mTT, Ri and TTP.

However, significant differences were found for pE center of lesion vs surrounding liver ( $p < 0.0001$ ) and center of lesion vs margin of lesion ( $p < 0.005$ ). No significant differences were found for pE surrounding liver vs margin of lesion ([Fig 1](#)). The 95% confidence intervals (CI) of difference were 1067 to 2845 for center vs. surrounding liver, -92.86 to 1685 for surrounding liver vs. margin and -2049 to -271.4 for center vs. margin.

The perfusion software uses pseudo-colors to show vascularization. Hypervascularization is shown in red and yellow shades ([Fig 2](#)). Devascularization is shown in blue and green colors. In all cases there was a profound visual reduction of vascularization displayed as blueish and greenish nuances ([Figs 3 and 4](#)).

### Discussion


Whereas surgical resection and ablation are widely accepted for curative care, trans-arterial chemoembolization remains the standard treatment option in patients with non-resectable HCC or if an ablative technique is not possible. The long-term results regarding tumor recurrence and overall survival are favorable compared to best supportive care [22]. Assessment of tumor response following interventional treatment is crucial for determination of treatment efficiency and further strategies.

Postinterventional success control following TACE and ablative techniques can be better evaluated by observing changes regarding the tumor vascularization rather than the size. Thus, CEUS is a valuable method for follow-up as it allows a continuous display of the microvascularization of a lesion [20, 23]. Previous CEUS studies have shown a sensitivity of 87–100% and a specificity of 65–100% in detecting residual tumor after TACE [24, 25]. Moschouris et al. used additionally perfusion quantification for HCC evaluation in both the pre- and post-TACE setting monitoring a statistically significant decrease in perfusion index (PI) after TACE [26].

**Table 1.** Mean  $\pm$  SD of pE, WiAuC, mTT, TTP and Ri each in the center of the lesion, the margins and the periphery, collected within 24 h following TACE.

	center (mean $\pm$ SD)	margin (mean $\pm$ SD)	Surrounding liver (mean $\pm$ SD)
<b>pE</b>	$867.8 \pm 2416$	$2028 \pm 3954$	$2824 \pm 4290$
<b>WiAuC</b>	$385.4 \pm 1262$	$564.6 \pm 954.9$	$1149 \pm 4473$
<b>mTT</b>	$211.3 \pm 195.0$	$184.1 \pm 150.6$	$163.8 \pm 157.1$
<b>TTP</b>	$24.15 \pm 13.97$	$22.40 \pm 11.70$	$20.93 \pm 10.69$
<b>Ri</b>	$19.84 \pm 13.51$	$18.08 \pm 10.35$	$16.78 \pm 9.91$

<https://doi.org/10.1371/journal.pone.0217599.t001>




**Fig 1. Comparison of all perfusion parameters.** Significant differences were only observed for Peak (up left) when comparing the center of the lesion (center column) versus the surrounding liver tissue (left column) center of the lesion vs. its margins (right column).

<https://doi.org/10.1371/journal.pone.0217599.g001>

The color coded perfusion software (VueBox) used in this study shows hyper enhancement in yellow and red shades, whereas devascularized areas appear blue. By using ROIs in the center of the lesion, the margins and the surrounding liver tissue the extent of devascularization could be analyzed. The therapeutic success postulates a near complete devascularization of the center of the malignant lesion as well as its border area. Nodular enhancement and irregular regional enhancement pattern correlate with residual vital tumor. However, contrast enhancement 24 hours after the ablation can either be evoked by reactive changes in terms of immunoresponses [27, 28] or remaining tumor. Thus, for TACE, the use of CEUS for follow-up within 24 hours post-intervention would not change the diagnostic and therapeutic setting. Previous studies have evaluated the perfusion parameters of gastrointestinal stoma tumors (GIST) [29] and prostate cancer [30]. However, this is the first time that a perfusion software was used for evaluation of the therapeutic success following TACE in HCC.


A critical point is, that the perfusion software often shows incomplete devascularization following TACE. Therefore, for establishing the clinical success, long-term follow-up is crucial. In this study, we were able to analyze and compare various perfusion parameters including peak enhancement, Wash-in area under the curve, mean transit time and time to peak in the center of the lesion, its border area and the periphery for the first time.

Our study had some limitations. The study population was heterogeneous with regard to the tumor sizes and the extent of liver cirrhosis. A further limitation is the still relatively small number of patients and lesions in the present study. Therefore, further studies with an increased number of patients are necessary. Also, the quality of CEUS examinations and thus




**Fig 2. Pre-interventional evaluation for peak enhancement.** A. Before embolization, the tumor and margin area show a profound enhancement in CEUS original images. B. In pseudo-colors the tumor is displayed in red colors. C. TIC analyses show that the perfusion curve for the center of the lesion (green) has a profound rise and fall consistent with a HCC.

<https://doi.org/10.1371/journal.pone.0217599.g002>



**Fig 3. Case of successful TACE (display of peak enhancement).** A. After the intervention, the post-embolization defect in CEUS original images appears black, meaning nearly avascular. B. In pseudo-colors the defect is shown in blue colors, also showing a devascularization. C. TIC analyses show that the perfusion curve for the center of the defect (green) is close to the baseline.

<https://doi.org/10.1371/journal.pone.0217599.g003>



**Fig 4. Case of a partially successful TACE (display of peak enhancement).** A. The post-embolization defect in CEUS original images shows residual contrast enhancement, consistent with remaining tumor. B. In pseudo-colors the defect is shown in blue to green colors, proving an only partial devascularization. C. TIC analyses show that the perfusion curve for the center of the defect (green) is not quite close to the baseline confirming residual tumor.

<https://doi.org/10.1371/journal.pone.0217599.g004>

VueBox evaluation strongly depends on the localization of the tumor lesion, as lesions in deeper layers are harder to visualize. Compared to other imaging modalities, CEUS requires specific technology and an experienced examiner and highly depend on the patient's compliance regarding breathing and circulation.

However, due to the relatively low costs, compared to imaging modalities such as CT or MRI ultrasound and CEUS in particular is a valuable tool for repeating post-interventional follow-up examinations. Also, the contrast agents used in CEUS have a reduced risk profile in comparison to CT and MRI regarding renal and thyroid function and potential allergic risks.

In summary, it can be said that the contrast-enhanced ultrasound in combination with perfusion analysis is a valuable supporting tool for post-interventional success control following TACE of liver lesions.

## Supporting information

**S1 Dataset. Data for perfusion parameter evaluation following TACE.**  
(XLSX)

## Author Contributions

**Data curation:** Lukas Philip Beyer, Philipp Wiggemann, Ernst Michael Jung.

**Formal analysis:** Andreas Schicho.

**Investigation:** Janine Rennert, Isabel Wiesinger, Ernst Michael Jung.

**Supervision:** Christian Stroszczynski, Ernst Michael Jung.

**Validation:** Janine Rennert.

**Writing – original draft:** Janine Rennert, Isabel Wiesinger.

**Writing – review & editing:** Lukas Philip Beyer, Ernst Michael Jung.

## References

1. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *Journal of hepatology*. 2012; 56(4):908–43. Epub 2012/03/20. <https://doi.org/10.1016/j.jhep.2011.12.001> PMID: 22424438.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA: a cancer journal for clinicians*. 2005; 55(2):74–108. Epub 2005/03/12. PMID: 15761078.
3. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. *Hepatology (Baltimore, Md)*. 2006; 43(6):1303–10. Epub 2006/05/27. <https://doi.org/10.1002/hep.21176> PMID: 16729298.
4. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *Journal of hepatology*. 2001; 35(3):421–30. Epub 2001/10/11. PMID: 11592607.
5. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. *Liver cancer*. 2014; 3(3–4):458–68. Epub 2015/08/19. <https://doi.org/10.1159/000343875> PMID: 26280007; PubMed Central PMCID: PMC4531423.
6. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. *Hepatology international*. 2010; 4(2):439–74. Epub 2010/09/10. <https://doi.org/10.1007/s12072-010-9165-7> PMID: 20827404; PubMed Central PMCID: PMC2900561.
7. von Herbay A, Vogt C, Westendorff J, Haussinger D, Gregor M. Correlation between SonoVue enhancement in CEUS, HCC differentiation and HCC diameter: analysis of 130 patients with

- hepatocellular carcinoma (HCC). Ultraschall in der Medizin (Stuttgart, Germany: 1980). 2009; 30(6):544–50. Epub 2009/12/10. <https://doi.org/10.1055/s-0028-1109745> PMID: 19998208.
- 8. Wildner D, Schellhaas B, Strack D, Goertz RS, Pfeifer L, Fiessler C, et al. Differentiation of malignant liver tumors by software-based perfusion quantification with dynamic contrast-enhanced ultrasound (DCEUS). Clinical hemorheology and microcirculation. 2018. Epub 2018/06/06. <https://doi.org/10.3233/CH-180378> PMID: 29865043.
  - 9. Rubenthaler J, Paprottka KJ, Hameister E, Hoffmann K, Joiko N, Reiser M, et al. Malignancies after liver transplantation: Value of contrast-enhanced ultrasound (CEUS) Liver transplantation for hepatocellular carcinoma. Clinical hemorheology and microcirculation. 2016; 64(3):467–73. Epub 2016/12/10. <https://doi.org/10.3233/CH-168117> PMID: 27935549.
  - 10. Lin MT, Wang CC, Cheng YF, Eng HL, Yen YH, Tsai MC, et al. Comprehensive Comparison of Multiple-Detector Computed Tomography and Dynamic Magnetic Resonance Imaging in the Diagnosis of Hepatocellular Carcinoma with Varying Degrees of Fibrosis. *PloS one*. 2016; 11(11):e0166157. Epub 2016/11/10. <https://doi.org/10.1371/journal.pone.0166157> PMID: 27829060; PubMed Central PMCID: PMC5102357.
  - 11. Jeon I, Cho ES, Kim JH, Kim DJ, Yu JS, Chung JJ. Feasibility of 10-Minute Delayed Hepatocyte Phase Imaging Using a 30 degrees Flip Angle in Gd-EOB-DTPA-Enhanced Liver MRI for the Detection of Hepatocellular Carcinoma in Patients with Chronic Hepatitis or Cirrhosis. *PloS one*. 2016; 11(12):e0167701. Epub 2016/12/10. <https://doi.org/10.1371/journal.pone.0167701> PMID: 27936106; PubMed Central PMCID: PMC5147964.
  - 12. Mise Y, Sakamoto Y, Ishizawa T, Kaneko J, Aoki T, Hasegawa K, et al. A worldwide survey of the current daily practice in liver surgery. *Liver cancer*. 2013; 2(1):55–66. Epub 2013/10/26. <https://doi.org/10.1159/000346225> PMID: 24159597; PubMed Central PMCID: PMC3747552.
  - 13. Lin SM. Local ablation for hepatocellular carcinoma in taiwan. *Liver cancer*. 2013; 2(2):73–83. Epub 2013/10/26. <https://doi.org/10.1159/000343843> PMID: 24159599; PubMed Central PMCID: PMC3740711.
  - 14. Chan SC. Liver transplantation for hepatocellular carcinoma. *Liver cancer*. 2013; 2(3–4):338–44. <https://doi.org/10.1159/000343849> PMID: 24400221.
  - 15. Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. *Liver cancer*. 2014; 3(2):119–24. Epub 2014/06/20. <https://doi.org/10.1159/000343867> PMID: 24945002; PubMed Central PMCID: PMC4057788.
  - 16. Kudo M. Biomarkers and Personalized Sorafenib Therapy. *Liver cancer*. 2014; 3(3–4):399–404. Epub 2015/08/19. <https://doi.org/10.1159/000343870> PMID: 26280001; PubMed Central PMCID: PMC4531426.
  - 17. Schicho A, Pereira PL, Michalik K, Beyer LP, Stroszczynski C, Wiggermann P. Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies. *Onco Targets Ther*. 2018; 11:345–50. <https://doi.org/10.2147/OTT.S147852> PMID: 29391811.
  - 18. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. *Cardiovascular and interventional radiology*. 2007; 30(1):6–25. Epub 2006/11/15. <https://doi.org/10.1007/s00270-006-0062-3> PMID: 17103105.
  - 19. Tranquart F, Mercier L, Frinking P, Gaud E, Ardit M. Perfusion quantification in contrast-enhanced ultrasound (CEUS)—ready for research projects and routine clinical use. *Ultraschall in der Medizin (Stuttgart, Germany: 1980)*. 2012; 33 Suppl 1:S31–8. Epub 2012/08/11. <https://doi.org/10.1055/s-0032-1312894> PMID: 22723027.
  - 20. Wiesinger I, Wiggermann P, Zausig N, Beyer LP, Salzberger B, Stroszczynski C, et al. Percutaneous Treatment of Malignant Liver Lesions: Evaluation of Success Using Contrast- Enhanced Ultrasound (CEUS) and Perfusion Software. *Ultraschall in der Medizin (Stuttgart, Germany: 1980)*. 2017. Epub 2017/09/26. <https://doi.org/10.1055/s-0043-119353> PMID: 28946152.
  - 21. Bulvik BE, Rozenblum N, Gourevich S, Ahmed M, Andriyanov AV, Galun E, et al. Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model. *Radiology*. 2016; 280(2):413–24. Epub 2016/07/20. <https://doi.org/10.1148/radiol.2015151166> PMID: 27429143.
  - 22. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology (Baltimore, Md)*. 2003; 37(2):429–42. Epub 2003/01/24. <https://doi.org/10.1053/jhep.2003.50047> PMID: 12540794.
  - 23. Piscaglia F, Nolsoe C, Dietrich CF, Cosgrove DO, Gilja OH, Bachmann Nielsen M, et al. The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS):

- update 2011 on non-hepatic applications. *Ultraschall in der Medizin* (Stuttgart, Germany: 1980). 2012; 33(1):33–59. Epub 2011/08/30. <https://doi.org/10.1055/s-0031-1281676> PMID: 21874631.
24. Kono Y, Lucidarme O, Choi SH, Rose SC, Hassanein TI, Alpert E, et al. Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma. *Journal of vascular and interventional radiology: JVIR*. 2007; 18(1 Pt 1):57–65. Epub 2007/02/14. <https://doi.org/10.1016/j.jvir.2006.10.016> PMID: 17296705.
25. Kim HJ, Kim TK, Kim PN, Kim AY, Ko EY, Kim KW, et al. Assessment of the therapeutic response of hepatocellular carcinoma treated with transcatheter arterial chemoembolization: comparison of contrast-enhanced sonography and 3-phase computed tomography. *Journal of ultrasound in medicine: official journal of the American Institute of Ultrasound in Medicine*. 2006; 25(4):477–86. Epub 2006/03/29. PMID: 16567437.
26. Moschouris H, Malagari K, Kornezos I, Papadaki MG, Gkoutzios P, Matsaidonis D. Unenhanced and contrast-enhanced ultrasonography during hepatic transarterial embolization and chemoembolization with drug-eluting beads. *Cardiovascular and interventional radiology*. 2010; 33(6):1215–22. Epub 2010/06/18. <https://doi.org/10.1007/s00270-010-9918-7> PMID: 20556386.
27. van den Bijgaart RJ, Eikelenboom DC, Hoogenboom M, Futterer JJ, den Brok MH, Adema GJ. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. *Cancer immunology, immunotherapy: CII*. 2017; 66(2):247–58. Epub 2016/09/03. <https://doi.org/10.1007/s00262-016-1891-9> PMID: 27585790; PubMed Central PMCID: PMCPMC5281669.
28. Bastianpillai C, Petrides N, Shah T, Guillaumier S, Ahmed HU, Arya M. Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment. *Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2015; 36(12):9137–46. Epub 2015/10/02. <https://doi.org/10.1007/s13277-015-4126-3> PMID: 26423402.
29. Lassau N, Chami L, Koscielny S, Chebil M, Massard C, Benatsou B, et al. Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masitinib. *Invest New Drugs*. 2012; 30(2):765–71. Epub 2010/12/08. <https://doi.org/10.1007/s10637-010-9592-2> PMID: 21136137.
30. Maxeiner A, Fischer T, Schwabe J, Baur ADJ, Stephan C, Peters R, et al. Contrast-Enhanced Ultrasound (CEUS) and Quantitative Perfusion Analysis in Patients with Suspicion for Prostate Cancer. *Ultraschall in der Medizin* (Stuttgart, Germany: 1980). 2018. Epub 2018/06/07. <https://doi.org/10.1055/a-0594-2093> PMID: 29874683.